Publication: LncRNA ADAMTS9-AS1 knockdown restricts cell proliferation and EMT in non-small cell lung cancer
| dc.contributor.author | Li, Zhongwen | |
| dc.contributor.author | Yue, Guojun | |
| dc.contributor.author | Zhang, Tingyou | |
| dc.contributor.author | Wu, Jinzhi | |
| dc.contributor.author | Tian, Xin | |
| dc.date.accessioned | 2023-01-26T11:39:51Z | |
| dc.date.available | 2023-01-26T11:39:51Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | A recent bioinformatics analysis identified long nonācoding RNA antisense 1 ADAMTS9-AS1 as an independent prognostic marker in several tumors, including prostate cancer and bladder cancer. Nevertheless, the prognostic value and functional role of ADAMTS9-AS1 in non-small cell lung cancer (NSCLC) remain elusive. Here, we first found that the expression of ADAMTS9-AS1 was significantly upregulated in NSCLC tissues compared with adjacent normal tissues using quantitative real time PCR analysis. Clinically, we observed that ADAMTS9-AS1 expression was associated with TNM stage, lymph node metastasis and poor prognosis in NSCLC patients. By performing lossof-function assay in A549 and 95D cells, our in vitro experiments further showed that knockdown of ADAMTS9-AS1 remarkedly suppressed cell proliferation, caused cell cycle G0/G1 arrest and apoptosis, and inhibited cell migration and invasion in NSCLC cells using CCK-8, colony formation, flow cytometry and transwell assays. Moreover, we found that ADAMTS9-AS1 knockdown downregulated the expression of CDK4, N-cadherin, Vimentin, but upregulated the expression of Bad and E-cadherin. In summary, our results revealed that ADAMTS9-AS1 may serve as a potential therapeutic target for the treatment of patients with NSCLC | es |
| dc.format | application/pdf | es |
| dc.format.extent | 10 | es |
| dc.identifier.citation | Histology and Histopathology Vol. 36, nĀŗ10 (2021) | |
| dc.identifier.doi | https://doi.org/10.14670/HH-18-347 | |
| dc.identifier.issn | 0213-3911 | |
| dc.identifier.issn | 1699-5848 | |
| dc.identifier.uri | http://hdl.handle.net/10201/127899 | |
| dc.language | eng | es |
| dc.publisher | Universidad de Murcia, Departamento de Biologia Celular e Histiologia | es |
| dc.relation | Sin financiación externa a la Universidad | es |
| dc.rights | info:eu-repo/semantics/openAccess | es |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | ADAMTS9-AS1 | es |
| dc.subject | NSCLC | es |
| dc.subject | Prognosis | es |
| dc.subject | Proliferation | es |
| dc.subject | EMT | es |
| dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - PatologĆa. Medicina clĆnica. OncologĆa | es |
| dc.title | LncRNA ADAMTS9-AS1 knockdown restricts cell proliferation and EMT in non-small cell lung cancer | es |
| dc.type | info:eu-repo/semantics/article | es |
| dspace.entity.type | Publication | es |
Este Ćtem estĆ” sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/